Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10818750 | 0.89 | ALDH1A1 (0.62) | GPR35KMT2AHTTALDH1A1HPGD | |
| SCHEMBL213849 | 0.89 | ALDH1A1 (0.62) | GPR35KMT2AHTTALDH1A1HPGD | |
| Ammonia Solution, Strong SCHEMBL11695961 | 0.87 | ALDH1A1 (0.60) | GPR35KMT2AHTTALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL10582751 | 0.87 | ALDH1A1 (0.60) | GPR35KMT2AHTTALDH1A1HPGD | |
| Alcohol SCHEMBL2355915 | 0.86 | GPR35 (0.55) | GPR35KMT2AHTTALDH1A1HPGD | |
| SCHEMBL10483657 | 0.85 | ALDH1A1 (0.50) | GPR35KMT2AHTTALDH1A1HPGD | |
| Trinitrophenol SCHEMBL28577416 | 0.82 | GPR35 (0.69) | GPR35KMT2AHTTALDH1A1HPGD | |
| SCHEMBL1537703 | 0.81 | GPR35 (0.46) | GPR35KMT2AHTTALDH1A1HPGD | |
| SCHEMBL9452637 | 0.80 | ALDH1A1 (0.61) | GPR35KMT2AHTTALDH1A1HPGD | |
| SCHEMBL31053016 | 0.80 | GPR35 (0.66) | GPR35KMT2AHTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116271-A1 | TACROLIMUS-CONTAINING OIL-IN-WATER TYPE CREAMY COMPOSITION | MARUHO CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20100190695-A1 | LIQUID CRYSTAL EMULSION TYPE PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSPORINE, AND THEREPEUTIC METHOD OF TREATING CUTANEOUS DISEASE THEREWITH | MARUHO CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2193798-A1 | LIQUID CRYSTAL EMULSION-TYPE PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSPORINE, AND METHOD OF TREATING CUTANEOUS DISEASE THEREWITH | Maruho Co., Ltd. (JP) | 2010-06-09 | — | — | EP | disclosed |
| CN-100574769-C | Nerve growth factor production inhibitor and skin preparations for extenal use, cosmetics, medicine part outer article, pruritus prevention and the therapeutic agent and the atopic dermatitis therapeutic agent that are combined with this nerve growth factor production inhibitor | PIAS ARISE KK | 2009-12-30 | — | — | CN | disclosed |
| CN-101035551-A | Nerve growth factor production inhibitor and external preparation for skin, cosmetic, quasi medicine, itch prophylactic and therapeutic agent and atopic dermatitis therapeutic agent mixed with the ner | PIAS ARISE KK (JP) | 2007-09-12 | — | — | CN | disclosed |
| US-20060094737-A1 | Novel uracil derivatives and medicinal use thereof | SUMITOMO PHARMACEUTICALS CO. LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1541562-A1 | NOVEL URACIL DERIVATIVES AND MEDICINAL USE THEREOF | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0649902-B1 | Method for screening of prophylactic and therapeutic agents for IgE-related diseases | RA CHISEI (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-5874404-A | Immunoglobulin E receptor α-chain inhibits IgE production and secondary allergic responses | Ra, Chisei (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0649902-A1 | Animal model for use in screening of prophylactic and therapeutic agents for IgE-related diseases | Ra, Chisei (JP) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094737-A1 | Novel uracil derivatives and medicinal use thereof | HRH3, HRH4, HRH2 | GPR35 3129/4885KMT2A 2563/4885HTT 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.